A detailed history of Jpmorgan Chase & CO transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,864,857 shares of HALO stock, worth $135 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,864,857
Previous 3,071,854 6.74%
Holding current value
$135 Million
Previous $161 Million 1.9%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$51.3 - $64.42 $10.6 Million - $13.3 Million
-206,997 Reduced 6.74%
2,864,857 $164 Million
Q2 2024

Aug 12, 2024

SELL
$37.81 - $52.4 $6.38 Million - $8.84 Million
-168,643 Reduced 5.2%
3,071,854 $161 Million
Q1 2024

May 10, 2024

BUY
$33.68 - $41.95 $4.94 Million - $6.15 Million
146,565 Added 4.74%
3,240,497 $132 Million
Q4 2023

Feb 12, 2024

SELL
$33.32 - $42.1 $2.31 Million - $2.92 Million
-69,333 Reduced 2.19%
3,093,932 $114 Million
Q3 2023

Nov 14, 2023

SELL
$36.46 - $44.03 $12.1 Million - $14.6 Million
-331,830 Reduced 9.49%
3,163,265 $121 Million
Q2 2023

Aug 11, 2023

SELL
$30.28 - $38.74 $838,180 - $1.07 Million
-27,681 Reduced 0.79%
3,495,095 $126 Million
Q1 2023

May 18, 2023

BUY
$32.86 - $55.7 $11 Million - $18.6 Million
334,418 Added 10.49%
3,522,776 $135 Million
Q1 2023

May 11, 2023

SELL
$32.86 - $55.7 $1.3 Million - $2.2 Million
-39,419 Reduced 1.22%
3,188,358 $122 Million
Q4 2022

Feb 13, 2023

SELL
$40.06 - $59.44 $28.3 Million - $41.9 Million
-705,249 Reduced 17.93%
3,227,777 $184 Million
Q3 2022

Nov 14, 2022

SELL
$38.53 - $51.78 $6 Million - $8.06 Million
-155,616 Reduced 3.81%
3,933,026 $156 Million
Q2 2022

Aug 11, 2022

SELL
$37.35 - $48.3 $35.5 Million - $45.9 Million
-951,129 Reduced 18.87%
4,088,642 $180 Million
Q1 2022

May 11, 2022

SELL
$31.97 - $41.06 $2.77 Million - $3.55 Million
-86,530 Reduced 1.69%
5,039,771 $201 Million
Q4 2021

Feb 10, 2022

SELL
$31.82 - $40.75 $4.4 Million - $5.63 Million
-138,138 Reduced 2.62%
5,126,301 $206 Million
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $203 Million - $244 Million
5,264,439 New
5,264,439 $214 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.54B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.